NCT03312114View on ClinicalTrials.gov

Anti-PD-L1 and SAbR for Ovarian Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

November 9, 2017

Primary Completion Date

March 19, 2019

Study Completion Date

March 19, 2019

Conditions
Recurrent Epithelial Cancer of OvaryPrimary Peritoneal CarcinomaFallopian Tube Cancer
Interventions
DRUG

Avelumab

Avelumab\* (MSB0010718C; anti-PD-L1 is a fully human anti-PD- L1 IgG1 antibody)

Trial Locations (1)

75390

University of Texas Southwestern Medical Center, Dallas

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

University of Texas Southwestern Medical Center

OTHER